Novo Nordisk Releases Integrated Annual Report 2017
Novo Nordisk, a global healthcare company specialising in diabetes, obesity and other serious chronic diseases, published its Annual Report 2017 online today at novonordisk.com/annualreport. It is the company's fourteenth integrated annual report accounting for the company's financial, social and environmental performance.
Since 2004, Novo Nordisk has published an integrated report to reflect the Novo Nordisk Triple Bottom Line business principle. The report includes financial, environmental and social statements for the year, as well as a management review. As a participant to the UN Global Compact, Novo Nordisk also submits a Communication on Progress report, detailing how company principles are translated into concrete actions with regards to human rights, labour, environment and anti-corruption.
“The actions we take will inevitably impact people, communities and the environment. That’s why we use the Triple Bottom Line principle to guide decisions and always strive to achieve a good balance between financial, social and environmental dimensions of performance. We want to maximise our positive impacts and minimise any adverse impacts of our business. This is what doing business responsibly means to us,” explains Lars Fruergaard Jørgensen, president and CEO.
The management review presents the company’s strategy and actions to be a sustainable business. Highlights are:
- Approval in the US and recommendation for approval in Europe of Ozempic®, a once-weekly, injectable GLP-1 treatment for adults with type 2 diabetes.
- Approvals in the EU and the US of Fiasp®, a new fast-acting mealtime insulin, for the treatment of adults with diabetes.
- Label update for Tresiba® in the EU, based on data from trials demonstrating a clinically relevant reduction in hypoglycaemia compared with insulin glargine U100.
- Label updates for Victoza® in the EU and the US, reflecting the product’s ability to reduce the risk of cardiovascular events in adults with type 2 diabetes and at high risk of cardiovascular disease.
- Net sales at DKK 112 billion – a sales growth of 2% measured in local currencies
- Operating profit at DKK 49 billion – 5% growth in local currencies.
- Diabetes care treatment provided to an estimated 27.7 million people with diabetes worldwide.
- Company reputation score of 79.3%.
- Zero failed quality inspections for the fifth year running.
- 79% of production powered by renewable energy
- 96% of waste recycled or reused
The full report can be downloaded as a PDF and will be available in print later this month.
Novo Nordisk Media Relations
Katrine Rud von Sperling
Novo Nordisk Investor Relations
Peter Hugreffe Ankersen